Please assess the completion status of the following clinical trial:

Trial Title: Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male or female subjects of any race, age 12 or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study;~* Facial acne vulgaris characterized by the following:~IGA Score \>3 10-50 facial inflammatory lesions (papules,pustules) 10-100 facial non-inflammatory lesions (open/closed comedones)~* Able to understand and comply with the requirements of the study and sign Informed Consent/HIPAA Authorization forms~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test), breast feeding, or who are of childbearing potential and not practicing a reliable method of birth control.~* Allergy/sensitivity to any component of the test treatment (Section 5.2), lincomycin, tetracyclines, or sulfites.~* Subjects who have not complied with the proper wash-out periods for prohibited medications/procedures (Supplement 1)\>~* History of clinically significant anemia or hemolysis.~* History of enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis).~* Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris~* Evidence of recent alcohol or drug abuse~* Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study~* History of poor cooperation, non-compliance with medical treatment or unreliability~* Participation in an investigational drug study within 30 days of the baseline visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- doxy + aczone (Type: EXPERIMENTAL): Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response

Based on this trial design, predict the completion outcome and termination type (if applicable).